Overview of Etopor 100 mg (Etoposide) Injection
Etopor 100 mg, containing the active ingredient Etoposide, is a potent cytotoxic chemotherapy drug used for the treatment of small cell lung cancer (SCLC). Developed by Eskayef Pharmaceuticals Ltd. and distributed globally by Saif Pharma, Etopor plays a vital role in cancer therapy due to its proven effectiveness and precision in targeting malignant cells.
This injectable formulation is designed to be used in combination with other chemotherapy agents as part of a first-line treatment regimen, offering patients a chance for improved survival and quality of life.
Indications
Etopor 100 mg is indicated for the treatment of small cell lung cancer, particularly in conjunction with other approved chemotherapeutic agents. It serves as a first-line treatment for patients diagnosed with this aggressive form of lung cancer.
Pharmacology
Etoposide belongs to the podophyllotoxin derivatives class. It works by inhibiting mitosis, specifically by blocking the assembly of microtubules and interfering with cell cycle progression during the late S and G2 phases. This disruption prevents cancer cell replication and promotes apoptosis (programmed cell death), making it an effective agent in cancer control.
Pha rmacokinetics
When administered intravenously, Etoposide displays a biphasic distribution:
Distribution Half-Life: ~1.5 hours
Elimination Half-Life: 4 to 11 hours
Clearance: Ranges from 33 to 48 ml/min
Volume of Distribution: 18 to 29 liters
The plasma concentration of Etopor increases linearly with dose and shows no accumulation with repeated daily dosing.
Dosage & Administration
Recommended Dosage for SCLC
35 mg/m²/day for 4 days, or
50 mg/m²/day for 5 days, in combination with other chemotherapeutic drugs.
Dosage may vary based on physician direction.
Creatinine clearance > 50 mL/min: 100% of dose
15–50 mL/min: Reduce dose to 75%
<15 mL/min: Caution advised, further reduction needed
Etopor should always be administered under strict medical supervision, preferably through slow intravenous infusion over 30–60 minutes to avoid hypotension.
Drug Interactions
Concomitant administration with high-dose Cyclosporine A (>2000 ng/ml) can:
Increase Etoposide exposure by 80%
Decrease its clearance by 38%
Close monitoring and dosage adjustment may be necessary when combined with other chemotherapeutic agents or immunosuppressants.
Laboratory Monitoring
Patients undergoing treatment should have:
Regular complete blood counts (CBC)
Monitoring before and after each cycle
Baseline and follow-up platelet, WBC, and hemoglobin levels
These measures help manage toxicity risks and guide therapy adjustments.
Contraindications
Etopor is contraindicated in:
Patients with known hypersensitivity to Etoposide
Patients allergic to any of the formulation components
Side Effects
Etopor may cause a variety of adverse reactions, categorized below:
Hematologic Toxicity
Myelosuppression (dose-limiting)
Granulocyte & platelet nadirs
Fever, infection, and rare death due to neutropenia
Gastrointestinal Effects
Nausea, vomiting, mucositis
Mild to moderate severity
More common with oral than IV administration
Hypotension
Transient episodes post-infusion
Prevented by slow administration
Allergic Reactions
Anaphylactic-like responses (0.7–2%)
Symptoms: chills, fever, dyspnea, hypotension
Management: Stop infusion and administer corticosteroids or antihistamines
Other Adverse Reactions
Alopecia (up to 66% of patients, reversible)
Rash, urticaria, pruritus
Neurological and pulmonary symptoms (rare)
Severe skin reactions (e.g., Stevens-Johnson syndrome, TEN)
Pregnancy & Lactation
Category D: May cause fetal harm
Breastfeeding: Not recommended as Etoposide may be excreted in human milk
Precautions & Warnings
Myelosuppression risk: Frequent monitoring is essential
Patients with low albumin levels: Higher toxicity risk
Slow infusion necessary: To prevent hypotension and allergic reactions
Avoid rapid IV injection
Therapy should only continue if benefits outweigh the potential risks. In the case of severe reactions, discontinue use and initiate corrective measures.
Therapeutic Class
Cytotoxic Chemotherapy (Antineoplastic agent)
Store under refrigeration (2°–8°C)
Protect from light and moisture
Keep out of children’s reach
Follow proper handling and disposal procedures for cytotoxic drugs
Manufacturer Information
Eskayef Pharmaceuticals Ltd.
A leading pharmaceutical manufacturer in Bangladesh, Eskayef has a legacy of producing world-class medicines since 1990. Originally the Bangladesh operation of SK&F (USA), Eskayef is now part of Transcom Group and is globally respected for its premium quality pharmaceutical products.
🔗 Visit Manufacturer’s Website: www.skfbd.com
Supplier Information
Saif Pharma
Founded in 2014, Saif Pharma is a top oncology medicine supplier and distributor with a global footprint across 60+ countries, including the USA, Canada, Saudi Arabia, UAE, China, India, and Pakistan. Known for its dependable, affordable, and high-quality cancer medicines, Saif Pharma is committed to reducing the burden of cancer globally.
Conclusion
Etopor 100 mg (Etoposide) Injection stands as a cornerstone in the treatment of small cell lung cancer. Its strong efficacy profile, flexible dosing, and consistent quality make it a preferred choice among oncologists worldwide. Manufactured by Eskayef Pharmaceuticals Ltd. and distributed by Saif Pharma, Etopor ensures accessibility to life-saving cancer therapy at an affordable price. With careful patient monitoring and professional administration, Etopor continues to bring hope to thousands battling cancer.
